A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
AI-Driven CT Imaging Predicts Cardiac Events in Large UK Cohort
An AI tool analyzing CCTA images can predict future cardiovascular events and death in patients with suspected stable coronary artery disease.
•EurekAlert
AI Tool from UCLA Targets Undiagnosed Alzheimer's and Diagnostic Disparity
UCLA researchers developed an AI model using EHR data to better detect undiagnosed Alzheimer's disease, especially in underrepresented groups.
•EurekAlert
AI Model Improves Differentiation of Brain Tumor Progression from Radiation Necrosis on MRI
A York University-led study shows a novel AI using advanced MRI can distinguish between progressive brain tumors and radiation necrosis more accurately than human assessment.